Systematic Review of the Epidemiological Burden of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Across Europe: Current Evidence and EUROMENE Research Recommendations for Epidemiology. — CFSMEATLAS
Systematic Review of the Epidemiological Burden of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Across Europe: Current Evidence and EUROMENE Research Recommendations for Epidemiology.
Estévez-López, Fernando, Mudie, Kathleen, Wang-Steverding, Xia et al. · Journal of clinical medicine · 2020 · DOI
Quick Summary
This research review looked at how common ME/CFS is across Europe by examining studies published between 1994 and 2019. The researchers found very few good-quality studies on this topic, and the estimates of how many people have ME/CFS varied widely (from 0.1% to 2.2% of the population). The review concludes that we urgently need better, larger studies to understand how many Europeans actually have this condition.
Why It Matters
Understanding how many people in Europe have ME/CFS is essential for healthcare planning, research funding allocation, and recognizing the true disease burden. This review reveals a critical gap in our knowledge—very few reliable statistics exist—highlighting why better epidemiological research is urgently needed to give ME/CFS patients appropriate visibility and resources.
Observed Findings
Only 3 prevalence studies of ME/CFS met quality criteria in European literature (1994–2019)
Prevalence estimates ranged from 0.1% to 2.2% across included studies
Only 2 studies provided any incidence data for ME/CFS in Europe
Included studies used inconsistent case definitions and methodologies
Grey literature search identified additional research gaps in the EUROMENE network
Inferred Conclusions
European epidemiological research on ME/CFS prevalence and incidence is severely limited and inadequate
Variability in case definitions and study designs has prevented reliable estimates of disease burden across Europe
Future research must employ standardized case definitions (CDC-1994, Canadian Consensus Criteria, or IOM criteria) and community-based recruitment
Well-powered, properly designed epidemiological studies are a pressing priority for understanding ME/CFS in Europe
Remaining Questions
What is the true prevalence of ME/CFS in different European countries and populations?
Why do the few available prevalence estimates vary so widely, and which methodological factors most influence these differences?
What This Study Does Not Prove
This review does not prove what causes ME/CFS, nor does it establish actual prevalence rates with certainty—the wide variation (0.1–2.2%) reflects differences in study methods rather than true prevalence. It also cannot explain why certain populations may be more or less affected, as the small number and poor quality of existing studies limit firm conclusions.